(0.24%) 5 112.35 points
(0.33%) 38 365 points
(0.30%) 15 975 points
(-1.50%) $82.59
(5.25%) $2.02
(0.31%) $2 354.50
(0.01%) $27.54
(3.89%) $958.00
(-0.20%) $0.933
(-0.35%) $10.99
(-0.51%) $0.796
(1.68%) $93.41
2.91% $ 5.30
Live Chart Being Loaded With Signals
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD...
Stats | |
---|---|
Tagesvolumen | 8 000.00 |
Durchschnittsvolumen | 21 587.00 |
Marktkapitalisierung | 304.61M |
EPS | $0 ( 2024-03-06 ) |
Nächstes Ertragsdatum | ( $0.0600 ) 2024-05-22 |
Last Dividend | $0.00600 ( 2013-06-13 ) |
Next Dividend | $0 ( N/A ) |
P/E | 35.33 |
ATR14 | $0.0240 (0.45%) |
Kamada Ltd Korrelation
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Kamada Ltd Finanzdaten
Annual | 2023 |
Umsatz: | $144.76M |
Bruttogewinn: | $52.59M (36.33 %) |
EPS: | $0.170 |
FY | 2023 |
Umsatz: | $144.76M |
Bruttogewinn: | $52.59M (36.33 %) |
EPS: | $0.170 |
FY | 2022 |
Umsatz: | $129.34M |
Bruttogewinn: | $46.70M (36.11 %) |
EPS: | $-0.0518 |
FY | 2021 |
Umsatz: | $103.64M |
Bruttogewinn: | $30.33M (29.26 %) |
EPS: | $-0.0500 |
Financial Reports:
No articles found.
Kamada Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00600 | 2013-06-13 |
Last Dividend | $0.00600 | 2013-06-13 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.00600 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.72 | -- |
Div. Sustainability Score | 9.03 | |
Div.Growth Potential Score | 2.37 | |
Div. Directional Score | 5.70 | -- |
Year | Amount | Yield |
---|---|---|
2013 | $0.00600 | 0.06% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0574 | 1.500 | 8.85 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0235 | 1.200 | 9.22 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0398 | 1.500 | -0.669 | -1.003 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.554 | 0.800 | 5.56 | 4.45 | [0.8 - 2.5] |
cashRatioTTM | 1.122 | 1.500 | 4.88 | 7.32 | [0.2 - 2] |
debtRatioTTM | 0.0250 | -1.500 | 9.58 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 6.53 | 1.000 | 8.69 | 8.69 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0760 | 2.00 | 9.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.0278 | 2.00 | -0.0139 | -0.0278 | [0 - 20] |
debtEquityRatioTTM | 0.0364 | -1.500 | 9.85 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.389 | 1.000 | 6.84 | 6.84 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0587 | 1.000 | -0.827 | -0.827 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.496 | 1.000 | 8.36 | 8.36 | [0.2 - 2] |
assetTurnoverTTM | 0.410 | 0.800 | -0.598 | -0.478 | [0.5 - 2] |
Total Score | 9.03 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 35.73 | 1.000 | 6.49 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0398 | 2.50 | -0.430 | -1.003 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.0278 | 2.00 | -0.00928 | -0.0278 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0760 | 2.00 | 9.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.633 | 1.500 | 9.12 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0302 | 1.000 | -1.744 | 0 | [0.1 - 0.5] |
Total Score | 2.37 |
Kamada Ltd
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.